References
- O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes
F, et al. (2003) Imatinib compared with interferon and lowdose
cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
N Engl J Med 348:994-1004
- Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et
al. (2017) Long-term outcomes of imatinib treatment for chronic
myeloid leukemia. N Engl J Med 376:917-27
- Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus
imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med
362:2251-2259
- Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus
imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
New Engl J Med 362:2260-2270
- Hochhaus A, et al. (2016) Long-term benefits and risks of frontline
nilotinib vs imatinib for chronic myeloid leukemia in chronic phase :
5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044-54
- Cortes JE, et al. (2016) Final 5-year study results of DASISION : The
dasatinib versus imatinib study in treatment-naive chronic myeloid
leukemia patients trial. J Clin Oncol 34(20):2333-40
- Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et
al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine
kinase in the blast crisis of chronic myeloid leukemia and acute
lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med
344:1038-1042
- Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al.
(2001) Efficacy and safety of a specific inhibitor of the BCR-ABL
tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:
1031-1037
- Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva
MH, et al. (2011) Imatinib treatment duration is related to decreased
estimated glomerular filtration rate in chronic myeloid leukemia
patients. Ann Oncol 22:2073-2079
- Kitiyakara C, Atichartakarn V. (2002) Renal failure associated with a
specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial
Transplant 17:685-687
- Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P. (2010) Renal
failure associated with tyrosine kinase inhibitors—case report and
review of the literature. Leuk Res 34:123-127
- Pou M, Saval N, Vera M, Saurina A, Sole M, Cervantes F, et al. (2003)
Acute renal failure secondary to imatinib mesylate treatment in
chronic myeloid leukemia. Leuk Lymphoma 44:1239-1241
- Al Aly Z, Philoctete Ashley JM, Gellens ME, Gonzalez EA. (2005)
Thrombotic thrombocytopenic purpura in a patient treated with imatinib
mesylate: true association or mere coincidence? Am J Kidney Dis
45:762-768
- Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS.
(2005) Acute renal failure secondary to imatinib mesylate treatment in
prostate cancer. Ann Pharmacother 39:2136-2138
- Francois H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P.
(2008) Partial fanconi syndrome induced by imatinib therapy: a novel
cause of urinary phosphate loss. Am J Kidney Dis 51:298-301
- Shibuya Y, Matsuo K, Kosugi T, Gomi T. (2004) Pharmacokinetics and
side effects of imatinib mesilate (Glivec®) in a
hemodialysis patient with chronic myeloid leukemia. Journal of
Japanese Society for Dialysis Therapy 37:239-42
- Nakahara R, Sato Y, Itoh H. (2016) High-performance liquid
chromatographic ultraviolet detection of nilotinib in human plasma
from patients with chronic myeloid leukemia, and comparison with
liquid chromatography-tandem mass spectrometry. J Clin Lab Anal.
30,1028-1030
- Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA,
Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon
FX. (2007) Trough imatinib plasma levels are associated with both
cytogenetic and molecular responses to standard-dose imatinib in
chronic myeloid leukemia. Blood, 109, 3496-3499
- Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I,
Hayes M, Granvil C, Wang Y. (2012) Plasma exposure of imatinib and its
correlation with clinical response in the Tyrosine Kinase Inhibitor
Optimization and Selectivity Trial. Haematologica 97(5):731-738
- Baccarani M, et al. (2013) European Leukemia Net recommendations for
the management of chronic myeloid leukemia. Blood 122:872-884
- Nakahara R, Sumimoto T, Ogata M, Sato Y, Itoh H. (2019) Successful
determination of nilotinib dosage by therapeutic drug monitoring in a
patient with chronic myeloid leukemia developing hepatic dysfunction:
A case report. Clin Case Rep., 7:1419-1421
- Miura M. (2015) Therapeutic drug monitoring of imatinib, nilotinib,
and dasatinib for patients with chronic myeloid leukemia. Biol Pharm
Bull. 38(5):645-654
- Peng B, Lloyd P, Schran H. (2005) Clinical pharmacokinetics of
imatinib. Clin Pharmacokinet 44:879-94
- Ladda MA, Goralski KB. (2016) The Effects of CKD on cytochorome
P450‒medeiated drug metabolism. Adv Chronic Kidney Dis 23:67-75
- Uchida N, Kurata N, Shimada K, et al. (1995) Changes of hepatic
microsomal oxidative drug metabolizing enzymes in chronic renal
failure (eCRF) rats by partial nephrectomy. Jpn J Pharmacol 68:431-9